Patent ID: 9443060
Filing Date: 2016-09-13
CPC Classification: A61K,G01N,G16H,G16Z,Y10T

Claim Text:
1. A method for determining cardiovascular risk for an individual suspected of having, at risk for, or diagnosed with a Metabolic Syndrome, the method comprising: a) obtaining from the individual one or more biological parameters, wherein the biological parameters are selected from the group consisting of fasting Blood Glucose, Triglycerides, Hemoglobin A1c, body mass index, Aspartate Transferase and fasting Blood Insulin, and from the biological parameters: b) determining a Fayad/Schentag (FS) index, wherein the FS index is calculated as: wherein the FBG is Fasting Blood Glucose in mg/dl; the TG is Triglycerides in mg/dl; the HBA1c is hemoglobin A1c in %; the BMI is body mass index in kg/m (S) calculated as follows: and (D) calculated as follows: c) assign the FS index determined in b) to the individual, wherein the FS index is a value of greater than 60 and is thereby indicative that the individual is in need of therapy for Metabolic Syndrome or at risk for at least one cardiovascular complication associated with Metabolic Syndrome, the method further comprising: d). administering to the individual a drug, wherein the drug is used to treat or resolve Metabolic Syndrome and is a formulation comprising pH encapsulated glucose, wherein said glucose from said pH encapsulated glucose formulation is targeted for release in the ileum of said individual, wherein conditions for release of said glucose from said pH encapsulated glucose formulation are a pH at or above a pH of 7.0.